Enasidenib works by selectively inhibiting the mutant IDH2 enzyme. This inhibition leads to a reduction in the levels of the oncometabolite 2-hydroxyglutarate (2-HG). Elevated levels of 2-HG are associated with the blockage of cellular differentiation, a hallmark of cancer. By reducing 2-HG levels, enasidenib promotes the differentiation of leukemic cells into normal blood cells, thereby alleviating the disease.